리포좀 개질화된 로즈마린산의 특성 분석과 항암 . 항산화 효과

이슬기; 최준식; 노주예; Seulgi Lee; Joon Sig Choi; Ju-Ye Ro

Polymer(Korea), Vol.45, No.4, 520-524, July, 2021

DOI10.7317/pk.2021.45.4.520 Export Citation

리포좀 개질화된 로즈마린산의 특성 분석과 항암 . 항산화 효과

Development of PEGylated Rosmarinic acid Liposome for Anti-cancer and Anti-oxidant Effect

이슬기¹, 최준식^{2, 1}, 노주예^{1, †}

¹충남대학교 생물공학연구소
²충남대학교 생화학과

Seulgi Lee¹, Joon Sig Choi^{2, 1}, and Ju-Ye Ro^{1, †}

¹Institute of Biotechnology, Chungnam National University, 99 Daehak-ro, Daejeon 34134, Korea
²Department of Biochemistry, Chungnam National University, 99 Daehak-ro, Daejeon 34134, Korea

E-mail:

초록

애플 민트(Mentha suaveolens)는 전통적으로 사용된 허브의 한 종류로써 저혈압, 진통, 항염 효과를 갖고 있다. 로즈마린 산(rosmarinic acid, RA)은 그 활성 성분으로 알려져 있다. RA는 항산화, 항세포사멸, 항암, 항염증과 같은 약리학적 효과를 나타내는 것으로 알려져 있다. 본 연구에서는 RA를 폴리에틸렌 글리콜과 리피드를 이용하여 리포좀화시켜 기존의 RA 보다 더 높은 약리학적 효과를 나타내는 약물전달체를 개발하였다. 광적동산란(dynamic light scattering), 제트 전위(zeta potential), 전계 방사형 주사전자현미경(field emission scanning electron microscopy) 등을 이용한 입자의 물리화학적 물성을 분석하고, 마우스 해마 유래 세포주인 HT22에서 항산화 효과 및 사람 유방암 유래 세포주인 MDA-MB- 231에서 확인하였다.

Apple mint (Mentha suaveolens) has been widely used in traditional herbal medicine since it shows hypotensive, analgesic, and anti-inflammatory effects. The active ingredient of apple mint is rosmarinic acid (RA), an ester of caffeic acid and 3,4-dihydroxyphenyl lactic acid. RA has many pharmacological effects, such as anti-oxidative, antiapoptotic, anti-tumorigenic, and anti-inflammatory properties. In this study, RA is incorporated in PEGylated liposomes to enhance its pharmacological effects. The physical characteristics of RA liposomes were demonstrated by dynamic light scattering, zeta potential, and field emission scanning electron microscopy. The anti-oxidation and anti-cancer effects of RA liposomes were evaluated in HT22 and MDA-MB-231 cell lines, respectively.

Keywords:rosmarinic acid;liposome;anti-cancer;anti-oxidant;drug delivery

[References]

Bulbake U, Doppalapudi S, Pharmaceutics, 9, 12 (2017)
Pattni BS, Chupin VV, Chem. Rev., 115, 0938 (2015)
Daraee H, Etemadi A, Artif. Cell Nanomed. B, 44, 381 (2016)
Akhtar A, Andleeb A, J. Control. Release, 330, 1152 (2020)
Li Z, Tan S, Cancer Drug Delivery in the Nano Era, 38, 611 2017.
Bonifacio BV, Silva PB, Int. J. Nanomed., 9, 1 (2014)
Immordino ML, Dosio F, Int. J. Nanomed., 1, 297 (2006)
Swamy MK, Sinniah UR, Ghasemzadeh A, Appl. Microbiol. Biotechnol., 102(18), 7775 (2018)
Anwar S, Shamsi A, Sci. Rep., 10, 10300 (2020)
Hase T, Shishido S, Sci. Rep., 9, 8711 (2019)
Lee S, Song SJ, Pharmaceutics, 12, 876 (2020)
Bukowski K, Kciuk M, Int. J. Molecular Sci., 21, 3233 (2020)
Messeha SS, Zarmouh NO, Eur. J. Pharmacol., 885, 173419 (2020)
Cao W, Hu C, J. Pharmacol. Sci., 132, 131 (2016)
Taguchi R, Hatayama K, Eur. J. Med. Chem., 138, 1066 (2017)
Ge LM, Zhu MJ, Food Hydrocoll., 83, 308 (2018)
Zhang Y, Hu M, J. Buon., 23, 763 (2018)

[1] Bulbake U, Doppalapudi S, Pharmaceutics, 9, 12 (2017)

[2] Pattni BS, Chupin VV, Chem. Rev., 115, 0938 (2015)

[3] Daraee H, Etemadi A, Artif. Cell Nanomed. B, 44, 381 (2016)

[4] Akhtar A, Andleeb A, J. Control. Release, 330, 1152 (2020)

[5] Li Z, Tan S, Cancer Drug Delivery in the Nano Era, 38, 611 2017.

[6] Bonifacio BV, Silva PB, Int. J. Nanomed., 9, 1 (2014)

[7] Immordino ML, Dosio F, Int. J. Nanomed., 1, 297 (2006)

[8] Swamy MK, Sinniah UR, Ghasemzadeh A, Appl. Microbiol. Biotechnol., 102(18), 7775 (2018)

[9] Anwar S, Shamsi A, Sci. Rep., 10, 10300 (2020)

[10] Hase T, Shishido S, Sci. Rep., 9, 8711 (2019)

[11] Lee S, Song SJ, Pharmaceutics, 12, 876 (2020)

[12] Bukowski K, Kciuk M, Int. J. Molecular Sci., 21, 3233 (2020)

[13] Messeha SS, Zarmouh NO, Eur. J. Pharmacol., 885, 173419 (2020)

[14] Cao W, Hu C, J. Pharmacol. Sci., 132, 131 (2016)

[15] Taguchi R, Hatayama K, Eur. J. Med. Chem., 138, 1066 (2017)

[16] Ge LM, Zhu MJ, Food Hydrocoll., 83, 308 (2018)

[17] Zhang Y, Hu M, J. Buon., 23, 763 (2018)